BiotechTube

Nivolumab/Ipilimumab

Phase 2UNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Transitional Cell Carcinoma

Conditions

Transitional Cell Carcinoma, Advanced Cancer, Metastatic Cancer

Trial Timeline

Jul 6, 2017 → Feb 18, 2023

NCT ID
NCT03219775

About Nivolumab/Ipilimumab

Nivolumab/Ipilimumab is a phase 2 stage product being developed by Bristol Myers Squibb for Transitional Cell Carcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT03219775. Target conditions include Transitional Cell Carcinoma, Advanced Cancer, Metastatic Cancer.

What happened to similar drugs?

0 of 9 similar drugs in Transitional Cell Carcinoma were approved

Approved (0) Terminated (3) Active (6)
🔄Vepugratinib + EV + PembrolizumabEli LillyPhase 3
❌AtezolizumabRochePhase 3
🔄vinflunine and best supportive careBristol Myers SquibbPhase 3
🔄padeliporfin VTPICON plc.Phase 3
🔄UGN-101 instillationsUroGen PharmaPhase 3
🔄NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3
❌NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03219775Phase 2UNKNOWN
NCT02917772Phase 2Completed

Competing Products

20 competing products in Transitional Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
Enfortumab vedotinAstellas PharmaPhase 2
35
enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabineAstellas PharmaPhase 1/2
36
Pemetrexed + Gemcitabine + PlatinolEli LillyPhase 1/2
32
Vepugratinib + EV + PembrolizumabEli LillyPhase 3
47
durvalumab and tremelimumabAstraZenecaPhase 2
35
Docetaxel + vandetanib + PlaceboAstraZenecaPhase 2
35
MK-3475 and BCGMerckPhase 2
42
PembrolizumabMerckPhase 2
31
Everolimus + Everolimus + PaclitaxelNovartisPhase 2
27
BuparlisibNovartisPhase 2
35
BEZ235NovartisPhase 2
27
AtezolizumabRochePhase 3
32
Gemcitabine + Cisplatin + Sunitinib MalatePfizerPhase 2
27
vinflunine and best supportive careBristol Myers SquibbPhase 3
40
vinflunineBristol Myers SquibbPhase 2
35
DasatinibBristol Myers SquibbPre-clinical
26
Docetaxel + OxaliplatinSanofiPhase 2
35
CabazitaxelSanofiPhase 2/3
38
Rogaratinib (BAY1163877) + ChemotherapyBayerPhase 2/3
35
CG0070 Adenovirus VectorCG OncologyPhase 2/3
27